reMYND
Leuven
About reMYND
Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models. They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugs currently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $28.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2021)
- Website: remynd.com
- Phone: +32 16 75 14 20
Industries & Categories
Biotechnology, Clinical Trials, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/remynd-71066 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.